U.S. flag

An official website of the United States government

NM_003052.5(SLC34A1):c.272_292del (p.Val91_Ala97del) AND Hypercalcemia, infantile, 2

Germline classification:
Conflicting interpretations of pathogenicity (4 submissions)
Last evaluated:
Mar 8, 2024
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000223670.9

Allele description [Variation Report for NM_003052.5(SLC34A1):c.272_292del (p.Val91_Ala97del)]

NM_003052.5(SLC34A1):c.272_292del (p.Val91_Ala97del)

Gene:
SLC34A1:solute carrier family 34 member 1 [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
5q35.3
Genomic location:
Preferred name:
NM_003052.5(SLC34A1):c.272_292del (p.Val91_Ala97del)
Other names:
p.Val91_Ala97del
HGVS:
  • NC_000005.10:g.177386233_177386253del
  • NG_016223.1:g.6803_6823del
  • NM_001167579.2:c.272_292del
  • NM_003052.5:c.272_292delMANE SELECT
  • NP_001161051.1:p.Val91_Ala97del
  • NP_003043.3:p.Val91_Ala97del
  • NC_000005.9:g.176813233_176813253del
  • NC_000005.9:g.176813234_176813254del
  • NM_003052.4:c.272_292del
  • NM_003052.4:c.272_292del21
  • NM_003052.4:c.272_292delTCCCCAAGCTGCGCCAGGCTG
Links:
OMIM: 182309.0009; dbSNP: rs876661296
NCBI 1000 Genomes Browser:
rs876661296
Molecular consequence:
  • NM_001167579.2:c.272_292del - inframe_deletion - [Sequence Ontology: SO:0001822]
  • NM_003052.5:c.272_292del - inframe_deletion - [Sequence Ontology: SO:0001822]
Functional consequence:
no known functional consequence
Observations:
1

Condition(s)

Name:
Hypercalcemia, infantile, 2 (HCINF2)
Identifiers:
MONDO: MONDO:0014851; MedGen: C4310473; Orphanet: 300547; OMIM: 616963

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000280020OMIM
no assertion criteria provided
Pathogenic
(Oct 6, 2016)
germlineliterature only

PubMed (1)
[See all records that cite this PMID]

SCV001142351Reproductive Health Research and Development, BGI Genomics
no assertion criteria provided
Likely pathogenic
(Jan 6, 2020)
germlinecuration

SCV001478333MK Azim Lab, Mohammad Ali Jinnah University
no assertion criteria provided
Uncertain significance
(Jan 31, 2021)
maternalclinical testing

SCV004708193Molecular Genetics Laboratory, Biocruces Bizkaia Health Research Institute
no assertion criteria provided
Likely pathogenic
(Mar 8, 2024)
maternalclinical testing

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedmaternalyesnot providednot providednot providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedcuration
not providedgermlinenot providednot providednot providednot providednot providednot providedliterature only
South Asianmaternalyes1not providednot providednot providednot providedclinical testing

Citations

PubMed

Autosomal-Recessive Mutations in SLC34A1 Encoding Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia.

Schlingmann KP, Ruminska J, Kaufmann M, Dursun I, Patti M, Kranz B, Pronicka E, Ciara E, Akcay T, Bulus D, Cornelissen EA, Gawlik A, Sikora P, Patzer L, Galiano M, Boyadzhiev V, Dumic M, Vivante A, Kleta R, Dekel B, Levtchenko E, Bindels RJ, et al.

J Am Soc Nephrol. 2016 Feb;27(2):604-14. doi: 10.1681/ASN.2014101025. Epub 2015 Jun 5.

PubMed [citation]
PMID:
26047794
PMCID:
PMC4731111

Details of each submission

From OMIM, SCV000280020.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedliterature only PubMed (1)

Description

In a 3.5-year-old Polish girl with polyuria who was discovered to have nephrocalcinosis and high-normal serum calcium at age 18 months (HCINF2; 616963), Schlingmann et al. (2016) identified homozygosity for a 21-bp deletion (c.271_291del, NM_003052) in exon 4 of the SLC34A1 gene, resulting in the in-frame deletion of 7 amino acids (91del7). The deletion was found in heterozygosity in her unaffected parents, and was also present in the Exome Variant Server with an allele frequency of approximately 2.6% in the European American population; testing of a larger sample yielded an allele frequency of approximately 1.6% (8 of 512 alleles). The deletion was also detected in compound heterozygosity in 3 additional unrelated patients with infantile hypercalcemia: the second allele carried an L155P, W305X, or V408E mutation, respectively, in a 17-year-old Polish boy, a 3-year-old German girl, and a 6-year-old Belgian girl. Functional analysis in Xenopus oocytes showed that wildtype protein induced significant uptake of labeled phosphate, and the 91del7 mutant induced uptake comparable to wildtype. Both missense mutants did not induce uptake that was significantly different from that of noninjected control cells. In transiently transfected opossum kidney cells, the 91del7 mutant was found to be expressed both in intracellular compartments as well as at the plasma membrane, indicating partial retention of this variant inside the cell; however, both missense mutants showed complete intracellular retention of the mutant proteins with no detectable actin colocalization, in contrast to wildtype, which localized at the plasma membrane and colocalized with actin.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenot providednot providednot providednot providednot providednot providednot providednot provided

From Reproductive Health Research and Development, BGI Genomics, SCV001142351.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcurationnot provided

Description

NM_003052.4:c.272_292del in the SLC34A1 gene has an allele frequency of 0.025 in European (non-Finnish) subpopulation in the gnomAD database, including 41 homozygous occurrences. However, considering the prevalence of hypercalcemia in the general population is approximately 1% to 2% (NCBI Bookshelf, Hypercalcemia), and it is not lethal, we decided not to take the allele frequency as a strong benign evidence. This variant was identified in homozygous state in a girl who presented with incidental nephrocalcinosis and polyuria (PMID: 26047794). Functional analyses confirmed the impaired trafficking of NaPi-IIa-91del7 in HEK293 cells while phosphate uptake in the Xenopus oocyte system was largely preserved (PMID: 26047794). We interpret it as Pathogenic/Likely pathogenic. ACMG/AMP criteria applied: PS3, PM3, PM4.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From MK Azim Lab, Mohammad Ali Jinnah University, SCV001478333.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1South Asian1not providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1maternalyesnot providednot providednot provided1not providednot providednot provided

From Molecular Genetics Laboratory, Biocruces Bizkaia Health Research Institute, SCV004708193.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1maternalyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 20, 2024